The UC Investment Office-backed cancer drug developer cut the number of shares in the offering but priced them at the mid-point of its range.

UCL Technology Fund-backed gene therapy developer MeiraGTx has gone public on Nasdaq after raising $75m in proceeds in its initial public offering.

Liquidia Technologies, a spinout from UNC Chapel Hill, has filed to raise up to $57.5m in its initial public offering.

The cancer drug developer and Stanford spinout floated at the top of its range in an offering that could reach $129m.

Johns Hopkins-backed biopharmaceutical developer Allakos has filed for a $75m initial public offering after raising more than $160m in equity funding.

UC Investment Office-backed gene expression technology developer Constellation Pharmaceuticals has filed for an $86.3m initial public offering.

The UCL spinout has priced its shares at the top of its range and secured $150m in proceeds, up from its initial target of $100m.

The Northwestern University-backed neurologic disorder therapy developer floated at the top of its range, increasing the share volume at the same time.

The UCL spinout has set the pricing range at $15 to $17 and stands to raise nearly $144m in proceeds if underwriters take up their 30-day option.